SBIR/STTR Research Award
Non-invasive delivery of skin-targeted tetanus vaccines
Award amount
$0Program and phase
STTR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VAXIN INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: (Adapted from Applicant's Abstract) A major limitation with the
contemporary vaccination program as a preventative measure against tetanus is
the encumbrance associated with multiple needle-dependent injections. Our aim
is to develop a simple method for the delivery of tetanus vaccines by topical
application of an adenovirus-vectored vaccine patch. The hypothesis is that the
expression of the tetanus toxin C-fragment (tetC) in the outer layer of skin
can induce a systemic immune response against the toxin molecule. We have
demonstrated that a protective immune response against live Clostridium tetani
infection could be elicited in mice by a single topical application of a patch
containing an adenovirus vector encoding tetC. These studies will further
develop the vectored vaccine patch, and specifically determine whether this
novel approach for the delivery of vaccines can mobilize the immune repertoire
against tetanus in humans. In this project, the potential for a vectored
vaccine patch to elicit a protective immune response against tetanus in animals
with pre-existing immunity to adenovirus will be investigated. A new generation
of adenovirus vectors with reduced immunogenicity as well as enhanced
transduction efficiency for the outer layer of skin will be developed as novel
vaccine carriers. Efficacy of NIVS will be compared to those induced by other
means. The interaction between vectors and the host will be studied by
determining the fate of vector DNA. A Phase I human clinical trial for
evaluating the safety of a vectored vaccine patch will be conducted. The
overall goal of these experiments is to determine whether tetanus vaccines can
be effectively and safely delivered by a skin patch that requires a lower level
of skill in a needle-free manner.
PROPOSED COMMERCIAL APPLICATION:
Non-invasive vaccination onto the skin may boost vaccine coverage against tetanus because the procedure is simple, effective, painless, and safe, The development may also make vaccination programs less dependent upon medical resources.
Technology keywords
Not reported